Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues. For example, one of few known permissive animal models for oncolytic...

Descripción completa

Detalles Bibliográficos
Autores principales: Clubb, James H. A., Kudling, Tatiana V., Girych, Mykhailo, Haybout, Lyna, Pakola, Santeri, Hamdan, Firas, Cervera-Carrascon, Víctor, Hemmes, Annabrita, Grönberg-Vähä-Koskela, Susanna, Santos, João Manuel, Quixabeira, Dafne C. A., Basnet, Saru, Heiniö, Camilla, Arias, Victor, Jirovec, Elise, Kaptan, Shreyas, Havunen, Riikka, Sorsa, Suvi, Erikat, Abdullah, Schwartz, Joel, Anttila, Marjukka, Aro, Katri, Viitala, Tapani, Vattulainen, Ilpo, Cerullo, Vincenzo, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936529/
https://www.ncbi.nlm.nih.gov/pubmed/36817448
http://dx.doi.org/10.3389/fimmu.2023.1060540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936529/
https://www.ncbi.nlm.nih.gov/pubmed/36817448
http://dx.doi.org/10.3389/fimmu.2023.1060540

Ejemplares similares